Video

Dr. Ramakrishnan on Advancements With CAR T-cell Therapies in LBCL

Praveen Ramakrishnan, MD, MS, discusses the clinical implications of CAR T-cell therapy in large B-cell lymphoma.

Praveen Ramakrishnan, MD, MS, assistant professor, the Department of Internal Medicine, UT Southwestern Medical Center, discusses the clinical implications of CAR T-cell therapy in large B-cell lymphoma (LBCL).

After little progress was made in the treatment of diffuse large B-cell lymphoma for about a decade, the previous few years have presented key developments in the space, Ramakrishnan says. Novel biology-based strategies and advancements in cell therapies have given patients with LBCL a second opportunity to receive effective treatment, Ramakrishnan explains.

Although CAR T-cell therapy has shifted the needle in LBCL, more work needs to be done, Ramakrishnan continues. Additional research into CAR T-cell therapy in the future will further assist in understanding the biology of LBCL and how to best sequence therapies for patients, Ramakrishnan concludes.

Related Videos
Michael R. Grunwald, MD, FACP
Peter Forsyth, MD
John N. Allan, MD
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLL
Minoo Battiwalla, MD, MS
Kathleen N. Moore, MD, MS
Paolo Caimi, MD
Dr Oveisi on the Importance of Patient Counseling Prior to CAR T-Cell Therapy in Myeloma
Leo I. Gordon, MD
Janaki Neela Sharma, MD, University of Miami